Kala azar: Rare import and significant differential diagnosis;Kala azar: Seltener import und wichtige differenzialdiagnose

Internist

Volumn 47, Issue 8, 2006, Pages 825-834

  Sudeck, H ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Fever; Kala azar; Splenic lymphoma; Splenomegaly; Visceral leishmaniasis

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CD4 ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 4; MILTEFOSINE; PAROMOMYCIN;

ARTICLE; AUTOIMMUNE DISEASE; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; ENDEMIC DISEASE; FEVER; GERMANY; HEPATOSPLENOMEGALY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LABORATORY DIAGNOSIS; LEISHMANIASIS; LYMPHOMA; NONHUMAN; PANCYTOPENIA; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; RARE DISEASE; RELIABILITY; SPLEEN TUMOR; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY;

CRITICAL CARE; ENDEMIC DISEASES; HUMANS; LEISHMANIASIS, VISCERAL; LYMPHOMA; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; RARE DISEASES; TRAVEL;

EID: 33748498918     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00108-006-1674-z     Document Type: Article

References (26)

1. Berenguer J, Cosin J, Miralles P et al. (2000) Discontinuation of secondary antileishmanial prophylaxis in HIV-infected patients who have responded to highly active antiretroviral therapy. AIDS 14: 2946-2948
2. Bogdan C, Schonian G, Banuls AL, Hide M (2001) Visceral Leishmaniasis in a German child who had never entered a known endemic area: Case report and review of the literature. Clin Infect Dis 32: 302-306
3. Burchenal JH, Bowers RF, Haedicke TA (1947) Visceral leishmaniasis complicated by severe anemia - improvement following splenectomy. Am J Trop Med Hyg 27: 699-709
4. Girois SB, Chapuis F, Decullier E, Revol BG (2005) Adverse effects of antifungal therapies in invasive fungal infections: review and meta-analysis. Eur J Clin Microbiol Infect Dis 24: 119-130
5. Collin S, Davidson R, Ritmeijer K (2004) Conflict and kala-azar: determinants of adverse outcomes of kala-azar among 3000 patients treated by Médecins Sans Frontières - Holland in Southern Sudan (1999-2002). Clin Infect Dis 38: 612-619
6. De Brito T, Hoshino-Shimizu S, Neto VA (1975) Glomerular involvement in human kala-azar. Am J Trop Med Hyg 24: 9-18
7. Dereure J, Pratlong F, Reynes J (1998) Haemoculture as a tool for diagnosing visceral leishmaniasis in HIV-negative and positive patients. Bull World Health Organ 76: 203-206
8. Desjeux P (1992) Human leishmaniases: epidemiology and public health aspects. World Health Stat Q 45: 267-275
9. Guerin JP, Olliaro P, Sundar S et al. (2002) Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect Dis 2: 494-501
10. Ho M, Siongok TK, Lyerly WH, Smith DH (1982) Prevalence and disease spectrum in a new focus of visceral leishmaniasis in Kenya. Trans R Soc Trop Med Hyg 76: 741-746
11. Jebbari H, Davidson R (1998) Advances in leishmaniasis. Cur Opin Infect Dis 11: 535-539
12. Jha TK, Olliaro P, Thakur CP (1998) Randomised controlled trial of aminosidine (paromomycin) vs sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India. BMJ 61: 1200-1205
13. Kelly BL, Stetson DB, Locksley RM (2003) Leishmania major LACK antigen is required for efficient vertebrate parasitization. J Exp Med 198: 1689-1698
14. Magill AJ, Grogl M, Gasser RA (1993) Visceral infection caused by L. tropica in veterans of Operation Desert Storm. N Engl J Med 328: 1383-1387
15. Mazloumi Gavgani AS, Hodjati MH, Mohite H (2002) Effect of insecticide-impregnated dog collars on incidence of zoonotic visceral leishmaniasis in Iranian children: a matched-cluster randomised trial. Lancet 360: 374-379
16. Mbong N, Loiseau PM, Billion M, Robert-Gero M (1998) Mechanism of amphotericin b resistance in Leishmania d. promastigotes. Antimicrob Agents Chemother 42: 352-357
17. Murray HW, Berman JD, Davies C, Saravia N (2005) Advances in leishmaniasis. Lancet 366: 1561-1577
18. Perez-Molina J, Fortun J, Lopez-Velez R (1997) Anal ulcer and chronic diarrhea as manifestations of visceral leishmaniasis in a patient infected with human immunodeficiency virus. Trans R Soc Trop Med Hyg 91: 436-437
19. Pintado V, Martin-Rabadan P, Rivera ML et al. (2001) Visceral leishmaniasis in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients. A comparative study. Medicine (Baltimore) 80: 54-73
20. Pippard MJ, Moir D, Weatherall DJ (1986) Mechanisms of anemia in resistant visceral leishmaniasis. Ann Trop Med Parasitol 80: 317-323
21. Punda-Polic V, Bradaric N, Grgic D (1997) A 9 year-old with fever and severe muscle pains. Lancet 349: 1666
22. Sundar S, Jha TK, Thakur CP et al. (2002) Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 347: 1739-1746
23. Thakur CP, Kanyok TP, Pandey AK et al. (2000) Treatment of visceral leishmaniasis with injectable paromomycin (aminosidine). An open-label randomized phase-II clinical study. Trans R Soc Trop Med Hyg 94: 432-433
24. Thisyakorn U, Jongwutiwes S, Vanichsetakul P, Lertsapcharoen P (1999) Visceral leishmaniasis: the first indigenous case in Thailand. Trans R Soc Trop Med Hyg 93: 23-24
25. WHO (2005) TDR Seventeenth Programme Report
26. WHO (2001) The World Health Report 2001